Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

Researchers at Martin Luther University have developed groundbreaking RNA-based agents that offer high levels of protection ...

SAN FRANCISCO, CA, USA I March 13, 2025 I Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE ...

The companies aim to advance precision drug delivery by leveraging Gensaic’s AI-guided ligand discovery platform ... including small interfering RNA (siRNA), which is used to regulate gene ...

Curia announced expansion plans to its Glasgow, UK facility and provided updates on the ongoing expansion in Albuquerque, NM.

Judo has been formed around a drug discovery engine called STRIKE (Selectively Targeting RNA Into KidnEy) that generates ligand-RNA conjugate drugs designed to switch off disease-associated genes ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of two first-in-class clini ...

The Yorl business said it is now signing multiple new contracts with global market-leading pharmaceutical companies ...

Welcome to the 3 rd Annual RNAi – Based Therapeutics Summit: Overcoming Barriers for Targeted siRNA Therapeutics ... range of RNAi drugs from discovery to development and beyond, join us ...

Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company's Board of Directors, effective as of May 8, 2025 ...

Q4 2024 Earnings Call Transcript March 4, 2025 Wave Life Sciences Ltd. beats earnings expectations. Reported EPS is $0.17, expectations were $-0.17. Operator: Good morning and welcome to the Wave Life ...